/Moderna%20Inc%20HQ-by%20hapabapa%20via%20iStock.jpg)
Moderna (MRNA) shares more than doubled on Wednesday morning after the biotech giant posted promising late-stage clinical trial data for its mRNA-based cancer vaccine. In its press release, Moderna said its investigational treatment, intismeran autogene, developed with Merck (MRK), succeeded in the landmark INTerpath-001 Phase 3 study involving 1,137 high-risk melanoma patients.
Following the meteoric run on Aug. 19, Moderna stock is trading at nearly 5x its price at the start of this year.
